EXPERIENCE OF USE OF ETANERCEPT IN EARLY JUVENILE ANKYLOSING SPONDYLITIS


A.N. Fetisova, E.I. Alexeyeva, MD, T.M. Bzarova, N.I. Taybulatov, A.V. Starikova, A.V. Anikin, G.A. Bekdzhanyan

The article presents a case of debut juvenile ankylosing spondylitis, characterized by rapid development of asymmetric poliarticular syndrome, sacroiliitis, disability of patient, and low quality of life of the child and his family. Suppression of the activity of the pathological process was achieved due to the successful application of soluble receptors for tumor necrosis factor α, etanercept. The function of affected joints was completely recovered, and quality of life was significantly improved. Inactive phase of the disease during treatment with etanercept was recorded after 4 weeks, remission - at 7th month of treatment.

Similar Articles


Бионика Медиа